Published on 07/10/202507/10/2025 by Applied Scientist 68 / 100 Powered by Rank Math SEO SEO Score Dr. Daniel Herrero Rivera | Oncology | Best Researcher Award Medical Oncologist | HLA Moncloa University Hospital | Spain Dr. Daniel Herrero Rivera is a distinguished Spanish medical oncologist currently serving as Médico Especialista en Oncología Médica at the Hospital Universitario HLA Moncloa and ATRYS in Spain. With a solid foundation in clinical oncology and translational research, he has established himself as a promising figure in precision oncology and cancer immunotherapy. Dr. Daniel Herrero Rivera earned his medical degree from the Universidad Complutense de Madrid in 2014, followed by multiple advanced qualifications including a Master’s in Medical Oncology (SEOM certification, 2019), a Master’s in Genomic and Big Data Oncology (2020), and a Ph.D. in Molecular Biology, Biomedicine, and Clinical Research from the Universidad de Sevilla (2023). His scholarly contributions include numerous publications in high-impact journals such as European Urology Oncology, Clinical and Translational Oncology, and Radiotherapy and Oncology. He has co-authored several book chapters and presented research exploring the molecular and clinical aspects of cancer therapy, including gene expression signatures, pharmacogenomics, and immuno-oncology. Dr. Daniel Herrero Rivera’s research project on gene polymorphisms in prostate cancer, funded by Fundación Progreso y Salud, reflects his dedication to improving personalized cancer treatments. With 58 citations across 56 documents, 6 publications, and an H-index of 5, his work demonstrates growing academic influence. His commitment to advancing precision oncology and his multidisciplinary expertise place him among Spain’s emerging medical researchers dedicated to bridging clinical practice and molecular innovation in cancer management. Profile: Scopus | ORCID | Research Gate Featured Publication 1. Gonçalves, D., Ocanto, A., Meilán, E., Couñago, F., & et al. (2025). First Spanish experience with stereotactic MR-guided adaptive radiotherapy (SMART) in borderline resectable and locally advanced pancreatic cancer: A prospective study. Biomedicines, 13(2390). MDPI. 2. Herrero Rivera, D., Soriano Segura, M., Prato Varela, J. O., Brygadyr Medvid, Y., & López Martín, J. A. (2025). Complete remission with fourth-line immunotherapy after chemotherapy failure in a lung cancer patient with severe autoimmune disease: An unexpected turn in oncologic management. Cureus, 17(6), e86116. 3. Jiménez, N., Garcia de Herreros, M., Reig, Ò., Mellado, B., & et al. (2024). Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients. European Urology Oncology. Elsevier. 4. (2022). Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel. Pharmacogenomics. Future Medicine. 5. López Martín, S., & Herrero Rivera, D. (2020). Assessment of factors associated with the intake of folic acid in the periconceptional period. Journal of Gynecology and Women’s Health, 20(3). Juniper Publishers. 6. (2020). Assessment of prognostic and therapeutic factors in male breast cancer: An observational study of a southwest Spanish single center. Archives of Breast Cancer, 7(4), 155–163. Daniel Herrero Rivera | Oncology | Best Researcher Award
Dr. Daniel Herrero Rivera is a distinguished Spanish medical oncologist currently serving as Médico Especialista en Oncología Médica at the Hospital Universitario HLA Moncloa and ATRYS in Spain. With a solid foundation in clinical oncology and translational research, he has established himself as a promising figure in precision oncology and cancer immunotherapy. Dr. Daniel Herrero Rivera earned his medical degree from the Universidad Complutense de Madrid in 2014, followed by multiple advanced qualifications including a Master’s in Medical Oncology (SEOM certification, 2019), a Master’s in Genomic and Big Data Oncology (2020), and a Ph.D. in Molecular Biology, Biomedicine, and Clinical Research from the Universidad de Sevilla (2023). His scholarly contributions include numerous publications in high-impact journals such as European Urology Oncology, Clinical and Translational Oncology, and Radiotherapy and Oncology. He has co-authored several book chapters and presented research exploring the molecular and clinical aspects of cancer therapy, including gene expression signatures, pharmacogenomics, and immuno-oncology. Dr. Daniel Herrero Rivera’s research project on gene polymorphisms in prostate cancer, funded by Fundación Progreso y Salud, reflects his dedication to improving personalized cancer treatments. With 58 citations across 56 documents, 6 publications, and an H-index of 5, his work demonstrates growing academic influence. His commitment to advancing precision oncology and his multidisciplinary expertise place him among Spain’s emerging medical researchers dedicated to bridging clinical practice and molecular innovation in cancer management. Profile: Scopus | ORCID | Research Gate Featured Publication
1. Gonçalves, D., Ocanto, A., Meilán, E., Couñago, F., & et al. (2025). First Spanish experience with stereotactic MR-guided adaptive radiotherapy (SMART) in borderline resectable and locally advanced pancreatic cancer: A prospective study. Biomedicines, 13(2390). MDPI. 2. Herrero Rivera, D., Soriano Segura, M., Prato Varela, J. O., Brygadyr Medvid, Y., & López Martín, J. A. (2025). Complete remission with fourth-line immunotherapy after chemotherapy failure in a lung cancer patient with severe autoimmune disease: An unexpected turn in oncologic management. Cureus, 17(6), e86116. 3. Jiménez, N., Garcia de Herreros, M., Reig, Ò., Mellado, B., & et al. (2024). Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients. European Urology Oncology. Elsevier. 4. (2022). Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel. Pharmacogenomics. Future Medicine. 5. López Martín, S., & Herrero Rivera, D. (2020). Assessment of factors associated with the intake of folic acid in the periconceptional period. Journal of Gynecology and Women’s Health, 20(3). Juniper Publishers. 6. (2020). Assessment of prognostic and therapeutic factors in male breast cancer: An observational study of a southwest Spanish single center. Archives of Breast Cancer, 7(4), 155–163.